State Grid Dezhou Lingcheng District Power Supply Company: Accelerating Electricity, Empowering Collective Economy through E-commerce, "Blooming at Multiple Points"

DEZHOU, China, Sept. 1, 2024 /PRNewswire/ -- The power supply company has provided me with great help, ensuring timely delivery every day. We can enjoy high-quality service through our district manager if we have any electricity problems, "said Wang Pingping, a merchant at the Zhengjiazhai live streaming base in Lingcheng District, Dezhou City, Shandong Province on August 28th. Since the beginning of this year, Zhengjiazhai Town in Lingcheng District, Dezhou City, Shandong Province has integrated town resources, explored diversified development paths, and made every effort to build a town brand. State Grid Dezhou Lingcheng District Power Supply Company has provided full service, proposing two guarantee measures of high voltage quality standards and high power supply reliability requirements, which have helped activate the "one pool of spring water" for the development of village collective economy, achieved multi-point industrial development, and opened up a new path for wealth and income increase.

Based on characteristic products and market demand, the Party Committee and Government of Zhengjiazhai Town have integrated Kangshen Animal Husbandry Co., Ltd.'s "Kangshen Fresh Beef", "Handmade Beef Roll Candy", "Freshly Brewed Yogurt", and the persimmon Ruyi Party Building Joint Vegetable Planting Base to create the town's characteristic agricultural products, creating the "Juyou Zhengjiazhai" agricultural product brand. A "Regional Brand Display Zone" has been set up in the Red Magnetic Field Party Building Joint E-commerce Incubation Base, creating a live broadcast room "online market" and expanding sales channels. Build an e-commerce live streaming sales platform, open live streaming sales and beef sales through traditional e-commerce platforms and emerging live streaming platforms, with an annual net zero of 5.5 million yuan. Relying on the Red Magnetic Field Party Building Alliance Party Mass Service Center, we will create incubation bases, build e-commerce live streaming training rooms, invite professional teachers to conduct live streaming e-commerce training courses, focus on talent incubation, and cultivate 28 small and medium-sized live streaming practitioners.

The power supply company not only helped us solve our electricity problem, but also dispatched personnel to voluntarily assist us in live streaming sales, providing a way out for our agricultural product sales. Now we can start a business without leaving our homes, "said Wang Yuexin, the person in charge of Zhengjiazhai Town's e-commerce live streaming base. State Grid Dezhou Lingcheng District Power Supply Company has made efforts in voltage quality, power supply reliability, and power supply services, relying on digital technology to support the steady development of the e-commerce industry. To comprehensively understand the electricity needs of e-commerce enterprises, help customers solve electricity problems, and prepare for safe and stable electricity use in e-commerce. Since the beginning of the year, the company has organized staff to visit the town's e-commerce live streaming base and communicate with the person in charge of the town government's live streaming base on power supply service needs such as safe electricity use and electricity business. They have timely grasped the current situation and needs of the enterprise's electricity use, and tailored energy efficiency service improvement plans for the enterprise based on the actual situation of customers. At the same time, in response to the shortage of excellent live streaming talents, the power supply company has selected and trained relevant personnel to voluntarily assist the live streaming base in live streaming sales, enhance the market competitiveness of the assisted live streaming base, and help the town government sell characteristic agricultural products to all parts of the country.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

State Grid Dezhou Lingcheng District Power Supply Company: Accelerating Electricity, Empowering Collective Economy through E-commerce, "Blooming at Multiple Points"

NANJING, China, Sept. 14, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Ischemic Stroke (AIS). Sanbexin sublingual tablets is the first innovative drug in the world to be designated with the Breakthrough Therapy by the FDA for the treatment of stroke.

The Breakthrough Therapy designation stems from the provisions of 《Food and Drug Administration Safety and Innovation Act》. It is designed to expedite the development and regulatory review of drugs for treating serious diseases and addressing significant unmet medical needs. The designation will be beneficial for the drugs to obtain the FDA's guidance in the clinical development, accelerate the overseas clinical development process, and is also expected to significantly shorten the time for marketing review through the priority review designation.

The Breakthrough Therapy designation is based on the significant improvement in efficacy metrics demonstrated by the sublingual tablets in a previous clinical study. The data from a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical study in China for the treatment of AIS demonstrated that Sanbexin sublingual tablets significantly improved neurological recovery and independent living ability in patients with AIS compared to placebo, meeting the expected efficacy endpoints with a favorable safety profile. JAMA Neurology published the study's key findings online.

The designation will be beneficial for Simcere to obtain the FDA's guidance in the clinical development of Sanbexin sublingual tablets, accelerate the overseas clinical development process, and is also expected to significantly shorten the time for marketing review through the priority review designation.

According to a recent article in The Lancet, stroke is the second leading cause of death and disability worldwide, with 12 million new cases and 6.6 million deaths each year. Among them, acute ischemic stroke is the most common type of stroke, accounting for about 70% of all strokes, and constituting a heavy disease burden for all countries around the world. The efficacy of acute ischemic stroke treatment is highly time-dependent. Receiving treatment as early as possible will help patients to improve their disease outcome and avoid disability.

Sanbexin sublingual tablets is a brain cytoprotective agent composed of edaravone and dexborneol, two active ingredients with synergistic anti-oxidant and anti-inflammatory effects, which can significantly reduce brain cell injury or impairment caused by AIS. Such unique sublingual formulation can quickly disintegrate once in contact with the saliva once place under the tongue and can be absorbed into the blood through the sublingual venous plexus, which is expected to increase the flexibility of stroke treatment. Sequential therapy consisting of the marketed Sanbexin concentrated solution for Injection. These two formulae enable patients to receive a complete course of treatment in and outside of the hospital.

On June 28, 2023, the new drug application (NDA) for Sanbexin sublingual tablets in China is accepted by the National Medical Products Administration. The first indication is for the improvement of neurological symptoms, daily activities, and functional impairment due to AIS. Phase I clinical trials for Sanbexin sublingual tablets on healthy volunteers have been completed in the United States.

CONTACT: Haoyun Huang, huanghaoyun@simcere.com 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration